From: A methodological framework for drug development in rare diseases
Items | Examples |
---|---|
Type of database | Registry |
Objectives | Include extensive information on all forms of a given rare disease grouped within several main categories |
Database conception | Team composed of clinicians and databank professionals |
Recruitment sources | Nationwide recruited patients |
Inclusion/exclusion criteria | Number of variables collected per patient at each visit |
Follow-up characteristics: | Number of follow-up visits per year for each patient |
Main results | Launch date |
Total number of patients | |
Median duration of follow-up | |
Number of centers | |
Database perpetuation | Specific contacts with the coordinating team through e-mail, phone calls and local visits, periodic meetings with all affiliated centers. |
Technical aspects | Use of a secured Internet protocol into a safe database through a web interface and specification of the characteristics of the available export formats |
Ergonomic aspects | Rolling menus and data entry forms accessible to unskilled users |
Cross-linking of registries | In order to share and compare data with other similar registries in other nations |
Quality control | A data manager/technical team should be in charge of quality control, monitoring for data coherence, absence of duplicates, and transfer of data |
Organization/management rules | A charter describes general rules relating to organization and rules governing access to data |
Data sharing | Rules for sharing: for cross-centre studies, the respective centers must agree explicitly to share its anonymous data with other centers |
Confidentiality of patient records | All subjects receive a unique study-identification code, which anonymizes the records. Only the registry's main investigators know the code and are able to link an individual report to an individual patient |
Ethical considerations | Informed consent characteristics |
Funding sources, competing interests | To be extensively specified |